XML 70 R55.htm IDEA: XBRL DOCUMENT
v3.19.1

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2019 | Apr. 01, 2018
Sales by segment of business |  |
Sales to customers | $ 20,021 | $ 20,009
Percent Change (as a percent) | 0.10% |
U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 10,129 | 9,951
Percent Change (as a percent) | 1.80% |
International |  |
Sales by segment of business |  |
Sales to customers | $ 9,892 | 10,058
Percent Change (as a percent) | (1.70%) |
CONSUMER |  |
Sales by segment of business |  |
Sales to customers | $ 3,318 | 3,398
Percent Change (as a percent) | (2.40%) |
CONSUMER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,438 | 1,436
Percent Change (as a percent) | 0.20% |
CONSUMER | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,880 | 1,962
Percent Change (as a percent) | (4.20%) |
CONSUMER | Baby Care |  |
Sales by segment of business |  |
Sales to customers | $ 394 | 457
Percent Change (as a percent) | (14.00%) |
CONSUMER | Baby Care | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 87 | 97
Percent Change (as a percent) | (10.90%) |
CONSUMER | Baby Care | International |  |
Sales by segment of business |  |
Sales to customers | $ 307 | 360
Percent Change (as a percent) | (14.80%) |
CONSUMER | Beauty |  |
Sales by segment of business |  |
Sales to customers | $ 1,090 | 1,084
Percent Change (as a percent) | 0.60% |
CONSUMER | Beauty | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 588 | 611
Percent Change (as a percent) | (3.80%) |
CONSUMER | Beauty | International |  |
Sales by segment of business |  |
Sales to customers | $ 502 | 473
Percent Change (as a percent) | 6.20% |
CONSUMER | Oral Care |  |
Sales by segment of business |  |
Sales to customers | $ 367 | 379
Percent Change (as a percent) | (3.10%) |
CONSUMER | Oral Care | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 151 | 157
Percent Change (as a percent) | (3.50%) |
CONSUMER | Oral Care | International |  |
Sales by segment of business |  |
Sales to customers | $ 216 | 222
Percent Change (as a percent) | (2.80%) |
CONSUMER | OTC |  |
Sales by segment of business |  |
Sales to customers | $ 1,087 | 1,072
Percent Change (as a percent) | 1.30% |
CONSUMER | OTC | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 507 | 465
Percent Change (as a percent) | 9.10% |
CONSUMER | OTC | International |  |
Sales by segment of business |  |
Sales to customers | $ 580 | 607
Percent Change (as a percent) | (4.60%) |
CONSUMER | Women's Health |  |
Sales by segment of business |  |
Sales to customers | $ 225 | 243
Percent Change (as a percent) | (7.30%) |
CONSUMER | Women's Health | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 3 | 3
Percent Change (as a percent) | 4.20% |
CONSUMER | Women's Health | International |  |
Sales by segment of business |  |
Sales to customers | $ 222 | 240
Percent Change (as a percent) | (7.50%) |
CONSUMER | Wound Care/Other |  |
Sales by segment of business |  |
Sales to customers | $ 155 | 163
Percent Change (as a percent) | (4.80%) |
CONSUMER | Wound Care/Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 102 | 103
Percent Change (as a percent) | (0.90%) |
CONSUMER | Wound Care/Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 53 | 60
Percent Change (as a percent) | (11.60%) |
PHARMACEUTICAL |  |
Sales by segment of business |  |
Sales to customers | $ 10,244 | 9,844
Percent Change (as a percent) | 4.10% |
PHARMACEUTICAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 5,582 | 5,354
Percent Change (as a percent) | 4.30% |
PHARMACEUTICAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 4,662 | 4,490
Percent Change (as a percent) | 3.90% |
PHARMACEUTICAL | Immunology |  |
Sales by segment of business |  |
Sales to customers | $ 3,251 | 3,042
Percent Change (as a percent) | 6.90% |
PHARMACEUTICAL | Immunology | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 2,163 | 2,000
Percent Change (as a percent) | 8.10% |
PHARMACEUTICAL | Immunology | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,088 | 1,042
Percent Change (as a percent) | 4.50% |
PHARMACEUTICAL | Immunology | REMICADE® |  |
Sales by segment of business |  |
Sales to customers | $ 1,102 | 1,389
Percent Change (as a percent) | (20.60%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 774 | 916
Percent Change (as a percent) | (15.50%) |
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports |  |
Sales by segment of business |  |
Sales to customers | $ 76 | 142
Percent Change (as a percent) | (46.40%) |
PHARMACEUTICAL | Immunology | REMICADE® | International |  |
Sales by segment of business |  |
Sales to customers | $ 252 | 331
Percent Change (as a percent) | (23.60%) |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® |  |
Sales by segment of business |  |
Sales to customers | $ 524 | 518
Percent Change (as a percent) | 1.00% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 263 | 224
Percent Change (as a percent) | 17.00% |
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 261 | 294
Percent Change (as a percent) | (11.10%) |
PHARMACEUTICAL | Immunology | STELARA® |  |
Sales by segment of business |  |
Sales to customers | $ 1,405 | 1,061
Percent Change (as a percent) | 32.40% |
PHARMACEUTICAL | Immunology | STELARA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 882 | 652
Percent Change (as a percent) | 35.20% |
PHARMACEUTICAL | Immunology | STELARA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 523 | 409
Percent Change (as a percent) | 27.90% |
PHARMACEUTICAL | Immunology | TREMFYA® |  |
Sales by segment of business |  |
Sales to customers | $ 217 | 72
PHARMACEUTICAL | Immunology | TREMFYA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | 168 | 66
PHARMACEUTICAL | Immunology | TREMFYA® | International |  |
Sales by segment of business |  |
Sales to customers | 49 | 6
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 3 | 2
Percent Change (as a percent) | 19.50% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 0
Percent Change (as a percent) | 0.00% |
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 3 | 2
Percent Change (as a percent) | 19.50% |
PHARMACEUTICAL | Infectious Diseases |  |
Sales by segment of business |  |
Sales to customers | $ 846 | 830
Percent Change (as a percent) | 1.90% |
PHARMACEUTICAL | Infectious Diseases | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 357 | 333
Percent Change (as a percent) | 7.30% |
PHARMACEUTICAL | Infectious Diseases | International |  |
Sales by segment of business |  |
Sales to customers | $ 489 | 497
Percent Change (as a percent) | (1.70%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine |  |
Sales by segment of business |  |
Sales to customers | $ 211 | 210
Percent Change (as a percent) | 0.80% |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 12 | 14
Percent Change (as a percent) | (18.80%) |
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International |  |
Sales by segment of business |  |
Sales to customers | $ 199 | 196
Percent Change (as a percent) | 2.20% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® |  |
Sales by segment of business |  |
Sales to customers | $ 523 | 478
Percent Change (as a percent) | 9.50% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 315 | 273
Percent Change (as a percent) | 15.50% |
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 208 | 205
Percent Change (as a percent) | 1.50% |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES |  |
Sales by segment of business |  |
Sales to customers | $ 112 | 142
Percent Change (as a percent) | (21.70%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 30 | 46
Percent Change (as a percent) | (33.80%) |
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International |  |
Sales by segment of business |  |
Sales to customers | $ 82 | 96
Percent Change (as a percent) | (16.00%) |
PHARMACEUTICAL | Neuroscience |  |
Sales by segment of business |  |
Sales to customers | $ 1,629 | 1,559
Percent Change (as a percent) | 4.50% |
PHARMACEUTICAL | Neuroscience | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 723 | 624
Percent Change (as a percent) | 16.00% |
PHARMACEUTICAL | Neuroscience | International |  |
Sales by segment of business |  |
Sales to customers | $ 905 | 935
Percent Change (as a percent) | (3.20%) |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate |  |
Sales by segment of business |  |
Sales to customers | $ 214 | 173
Percent Change (as a percent) | 23.40% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 97 | 66
Percent Change (as a percent) | 47.70% |
PHARMACEUTICAL | Neuroscience | CONCERTA® / Methylphenidate | International |  |
Sales by segment of business |  |
Sales to customers | $ 116 | 107
Percent Change (as a percent) | 8.50% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® |  |
Sales by segment of business |  |
Sales to customers | $ 790 | 696
Percent Change (as a percent) | 13.50% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 483 | 400
Percent Change (as a percent) | 20.70% |
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 307 | 296
Percent Change (as a percent) | 3.80% |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® |  |
Sales by segment of business |  |
Sales to customers | $ 179 | 196
Percent Change (as a percent) | (8.80%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 77 | 82
Percent Change (as a percent) | (6.80%) |
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 102 | 114
Percent Change (as a percent) | (10.30%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE |  |
Sales by segment of business |  |
Sales to customers | $ 446 | 494
Percent Change (as a percent) | (9.60%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 66 | 76
Percent Change (as a percent) | (12.00%) |
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International |  |
Sales by segment of business |  |
Sales to customers | $ 379 | 418
Percent Change (as a percent) | (9.20%) |
PHARMACEUTICAL | Oncology |  |
Sales by segment of business |  |
Sales to customers | $ 2,518 | 2,311
Percent Change (as a percent) | 9.00% |
PHARMACEUTICAL | Oncology | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 962 | 933
Percent Change (as a percent) | 3.10% |
PHARMACEUTICAL | Oncology | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,556 | 1,378
Percent Change (as a percent) | 13.00% |
PHARMACEUTICAL | Oncology | DARZALEX® |  |
Sales by segment of business |  |
Sales to customers | $ 629 | 432
Percent Change (as a percent) | 45.50% |
PHARMACEUTICAL | Oncology | DARZALEX® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 352 | 264
Percent Change (as a percent) | 33.00% |
PHARMACEUTICAL | Oncology | DARZALEX® | International |  |
Sales by segment of business |  |
Sales to customers | $ 277 | 168
Percent Change (as a percent) | 65.10% |
PHARMACEUTICAL | Oncology | IMBRUVICA® |  |
Sales by segment of business |  |
Sales to customers | $ 784 | 587
Percent Change (as a percent) | 33.50% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 349 | 227
Percent Change (as a percent) | 53.70% |
PHARMACEUTICAL | Oncology | IMBRUVICA® | International |  |
Sales by segment of business |  |
Sales to customers | $ 435 | 360
Percent Change (as a percent) | 20.80% |
PHARMACEUTICAL | Oncology | VELCADE® |  |
Sales by segment of business |  |
Sales to customers | $ 263 | 313
Percent Change (as a percent) | (16.00%) |
PHARMACEUTICAL | Oncology | VELCADE® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 0
Percent Change (as a percent) | 0.00% |
PHARMACEUTICAL | Oncology | VELCADE® | International |  |
Sales by segment of business |  |
Sales to customers | $ 263 | 313
Percent Change (as a percent) | (16.00%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate |  |
Sales by segment of business |  |
Sales to customers | $ 679 | 845
Percent Change (as a percent) | (19.60%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 185 | 407
Percent Change (as a percent) | (54.50%) |
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International |  |
Sales by segment of business |  |
Sales to customers | $ 494 | 438
Percent Change (as a percent) | 12.90% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY |  |
Sales by segment of business |  |
Sales to customers | $ 163 | 134
Percent Change (as a percent) | 21.70% |
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 76 | 35
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International |  |
Sales by segment of business |  |
Sales to customers | $ 87 | 99
Percent Change (as a percent) | (12.20%) |
PHARMACEUTICAL | Pulmonary Hypertension |  |
Sales by segment of business |  |
Sales to customers | $ 656 | 585
Percent Change (as a percent) | 12.10% |
PHARMACEUTICAL | Pulmonary Hypertension | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 430 | 361
Percent Change (as a percent) | 19.20% |
PHARMACEUTICAL | Pulmonary Hypertension | International |  |
Sales by segment of business |  |
Sales to customers | $ 226 | 224
Percent Change (as a percent) | 0.70% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® |  |
Sales by segment of business |  |
Sales to customers | $ 306 | 271
Percent Change (as a percent) | 12.70% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 172 | 149
Percent Change (as a percent) | 15.90% |
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International |  |
Sales by segment of business |  |
Sales to customers | $ 133 | 122
Percent Change (as a percent) | 8.90% |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® |  |
Sales by segment of business |  |
Sales to customers | $ 117 | 140
Percent Change (as a percent) | (16.70%) |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 61 | 68
Percent Change (as a percent) | (10.10%) |
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® | International |  |
Sales by segment of business |  |
Sales to customers | $ 56 | 72
Percent Change (as a percent) | (22.90%) |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® |  |
Sales by segment of business |  |
Sales to customers | $ 198 | 140
Percent Change (as a percent) | 41.60% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 176 | 124
Percent Change (as a percent) | 41.40% |
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International |  |
Sales by segment of business |  |
Sales to customers | $ 22 | 16
Percent Change (as a percent) | 42.80% |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 35 | 34
Percent Change (as a percent) | 4.00% |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 21 | 20
Percent Change (as a percent) | 3.60% |
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 15 | 14
Percent Change (as a percent) | 4.60% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other |  |
Sales by segment of business |  |
Sales to customers | $ 1,345 | 1,517
Percent Change (as a percent) | (11.30%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 947 | 1,103
Percent Change (as a percent) | (14.10%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International |  |
Sales by segment of business |  |
Sales to customers | $ 398 | 414
Percent Change (as a percent) | (3.90%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® |  |
Sales by segment of business |  |
Sales to customers | $ 542 | 578
Percent Change (as a percent) | (6.30%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 542 | 578
Percent Change (as a percent) | (6.30%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 0
Percent Change (as a percent) | 0.00% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® |  |
Sales by segment of business |  |
Sales to customers | $ 202 | 248
Percent Change (as a percent) | (18.40%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 154 | 204
Percent Change (as a percent) | (24.80%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International |  |
Sales by segment of business |  |
Sales to customers | $ 49 | 44
Percent Change (as a percent) | 11.60% |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® |  |
Sales by segment of business |  |
Sales to customers | $ 226 | 276
Percent Change (as a percent) | (18.00%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 148 | 189
Percent Change (as a percent) | (21.60%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International |  |
Sales by segment of business |  |
Sales to customers | $ 78 | 87
Percent Change (as a percent) | (10.20%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 374 | 415
Percent Change (as a percent) | (9.70%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 104 | 132
Percent Change (as a percent) | (21.30%) |
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 271 | 283
Percent Change (as a percent) | (4.40%) |
MEDICAL DEVICES |  |
Sales by segment of business |  |
Sales to customers | $ 6,459 | 6,767
Percent Change (as a percent) | (4.60%) |
MEDICAL DEVICES | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 3,109 | 3,161
Percent Change (as a percent) | (1.60%) |
MEDICAL DEVICES | International |  |
Sales by segment of business |  |
Sales to customers | $ 3,350 | 3,606
Percent Change (as a percent) | (7.10%) |
MEDICAL DEVICES | Diabetes Care |  |
Sales by segment of business |  |
Sales to customers | $ 0 | 339
MEDICAL DEVICES | Diabetes Care | U.S. |  |
Sales by segment of business |  |
Sales to customers | 0 | 117
MEDICAL DEVICES | Diabetes Care | International |  |
Sales by segment of business |  |
Sales to customers | 0 | 222
MEDICAL DEVICES | Interventional Solutions |  |
Sales by segment of business |  |
Sales to customers | $ 732 | 640
Percent Change (as a percent) | 14.30% |
MEDICAL DEVICES | Interventional Solutions | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 343 | 304
Percent Change (as a percent) | 12.60% |
MEDICAL DEVICES | Interventional Solutions | International |  |
Sales by segment of business |  |
Sales to customers | $ 389 | 336
Percent Change (as a percent) | 15.80% |
MEDICAL DEVICES | Orthopaedics |  |
Sales by segment of business |  |
Sales to customers | $ 2,204 | 2,250
Percent Change (as a percent) | (2.10%) |
MEDICAL DEVICES | Orthopaedics | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,318 | 1,307
Percent Change (as a percent) | 0.90% |
MEDICAL DEVICES | Orthopaedics | International |  |
Sales by segment of business |  |
Sales to customers | $ 885 | 943
Percent Change (as a percent) | (6.20%) |
MEDICAL DEVICES | Orthopaedics | HIPS |  |
Sales by segment of business |  |
Sales to customers | $ 361 | 363
Percent Change (as a percent) | (0.40%) |
MEDICAL DEVICES | Orthopaedics | HIPS | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 213 | 209
Percent Change (as a percent) | 2.10% |
MEDICAL DEVICES | Orthopaedics | HIPS | International |  |
Sales by segment of business |  |
Sales to customers | $ 148 | 154
Percent Change (as a percent) | (3.80%) |
MEDICAL DEVICES | Orthopaedics | KNEES |  |
Sales by segment of business |  |
Sales to customers | $ 369 | 387
Percent Change (as a percent) | (4.70%) |
MEDICAL DEVICES | Orthopaedics | KNEES | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 223 | 228
Percent Change (as a percent) | (2.20%) |
MEDICAL DEVICES | Orthopaedics | KNEES | International |  |
Sales by segment of business |  |
Sales to customers | $ 146 | 159
Percent Change (as a percent) | (8.20%) |
MEDICAL DEVICES | Orthopaedics | TRAUMA |  |
Sales by segment of business |  |
Sales to customers | $ 685 | 696
Percent Change (as a percent) | (1.40%) |
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 417 | 407
Percent Change (as a percent) | 2.50% |
MEDICAL DEVICES | Orthopaedics | TRAUMA | International |  |
Sales by segment of business |  |
Sales to customers | $ 268 | 289
Percent Change (as a percent) | (7.00%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 788 | 804
Percent Change (as a percent) | (2.20%) |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 465 | 463
Percent Change (as a percent) | 0.30% |
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 323 | 341
Percent Change (as a percent) | (5.50%) |
MEDICAL DEVICES | Surgery |  |
Sales by segment of business |  |
Sales to customers | $ 2,395 | 2,423
Percent Change (as a percent) | (1.20%) |
MEDICAL DEVICES | Surgery | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 1,001 | 993
Percent Change (as a percent) | 0.80% |
MEDICAL DEVICES | Surgery | International |  |
Sales by segment of business |  |
Sales to customers | $ 1,394 | 1,430
Percent Change (as a percent) | (2.60%) |
MEDICAL DEVICES | Surgery | ADVANCED |  |
Sales by segment of business |  |
Sales to customers | $ 980 | 966
Percent Change (as a percent) | 1.50% |
MEDICAL DEVICES | Surgery | ADVANCED | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 404 | 393
Percent Change (as a percent) | 2.90% |
MEDICAL DEVICES | Surgery | ADVANCED | International |  |
Sales by segment of business |  |
Sales to customers | $ 576 | 573
Percent Change (as a percent) | 0.50% |
MEDICAL DEVICES | Surgery | GENERAL |  |
Sales by segment of business |  |
Sales to customers | $ 1,089 | 1,127
Percent Change (as a percent) | (3.40%) |
MEDICAL DEVICES | Surgery | GENERAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 425 | 423
Percent Change (as a percent) | 0.30% |
MEDICAL DEVICES | Surgery | GENERAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 665 | 704
Percent Change (as a percent) | (5.60%) |
MEDICAL DEVICES | Surgery | SPECIALTY |  |
Sales by segment of business |  |
Sales to customers | $ 325 | 330
Percent Change (as a percent) | (1.40%) |
MEDICAL DEVICES | Surgery | SPECIALTY | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 172 | 177
Percent Change (as a percent) | (2.50%) |
MEDICAL DEVICES | Surgery | SPECIALTY | International |  |
Sales by segment of business |  |
Sales to customers | $ 153 | 153
Percent Change (as a percent) | (0.20%) |
MEDICAL DEVICES | Vision |  |
Sales by segment of business |  |
Sales to customers | $ 1,129 | 1,115
Percent Change (as a percent) | 1.20% |
MEDICAL DEVICES | Vision | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 446 | 440
Percent Change (as a percent) | 1.50% |
MEDICAL DEVICES | Vision | International |  |
Sales by segment of business |  |
Sales to customers | $ 682 | 675
Percent Change (as a percent) | 1.10% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER |  |
Sales by segment of business |  |
Sales to customers | $ 824 | 807
Percent Change (as a percent) | 2.10% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 321 | 309
Percent Change (as a percent) | 4.10% |
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International |  |
Sales by segment of business |  |
Sales to customers | $ 502 | 498
Percent Change (as a percent) | 1.00% |
MEDICAL DEVICES | Vision | SURGICAL |  |
Sales by segment of business |  |
Sales to customers | $ 305 | 308
Percent Change (as a percent) | (1.10%) |
MEDICAL DEVICES | Vision | SURGICAL | U.S. |  |
Sales by segment of business |  |
Sales to customers | $ 125 | 131
Percent Change (as a percent) | (4.50%) |
MEDICAL DEVICES | Vision | SURGICAL | International |  |
Sales by segment of business |  |
Sales to customers | $ 180 | $ 177
Percent Change (as a percent) | 1.30% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_VELCADEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRACLEERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINEOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPECIALTYMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |